Memorial Sloan Kettering Cancer Center is using Optiscan’s technology in research for early detection, screening and intraoperative margin assessment including oral, oesophageal and cervical dysplasias and carcinoma in situ.

Optiscan is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) in New York City is using Optiscan technology in research efforts at the institution. MSK’s use of this technology will help Optiscan continue to develop novel tools for early detection, screening and intraoperative margin assessment including oral, oesophageal and cervical dysplasias and carcinoma in situ.